Loading clinical trials...
Loading clinical trials...
Mechanism of Isolevuglandin-Protein Adduct Formation in Persistent Immune Activation in Long COVID POTS
Conditions
Interventions
To Measure levels of circulating monocyte/ T cell doublets at Baseline
To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment
+5 more
Locations
1
United States
Cyndya Shibao
Nashville, Tennessee, United States
Start Date
December 18, 2025
Primary Completion Date
June 30, 2028
Completion Date
June 30, 2029
Last Updated
January 22, 2026
NCT05359991
NCT05421208
NCT05926505
NCT06590324
NCT05914649
NCT06435403
Lead Sponsor
Vanderbilt University Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions